Valuation always matters in investing. And sometimes you can find stocks that are especially great bargains.
This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3...
Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human Services Department is evaluating plans to slash the federal government funding for...
Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.DR-0201 is...
Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon, or approximately...
If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (NYSE: PFE) . The pharmaceutical giant isn't as risky an investment as it may appear to be. Its financials...
Healthcare is a defensive sector that is more resilient to economic downturns than most others. That's one of several reasons it is home to solid dividend stocks, including Pfizer (NYSE: PFE) and Bristol...
Investor enthusiasm hit a fever pitch following the 2024 election, but took a punch to the gut recently. Market indexes have been falling as investors are beginning to assume President Trump will make...
Last year, Summit Therapeutics (NASDAQ: SMMT) was one of the stars of the biotech industry. The company's shares soared following a significant clinical win. Summit's market capitalization of $15.3 billion...
You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of Retirement and Disability Policy says Social Security's funds might run out by 2037,...